Notice for International Patients & Caregivers
English summary does not mean the trial enrolls international patients. Multiple myeloma interventional clinical trials in China typically require valid Chinese resident identity/national healthcare insurance and strict adherence to China's Human Genetic Resources Administration regulations.
Therapy Focus
Snapshot: 2026-09-04
CAR-T Cell Therapy Active Trials in China
As of 2026-09-04, there are 15 active clinical trials investigating CAR-T Cell Therapy for multiple myeloma across 23 provinces and 69 study centers in China. Chimeric Antigen Receptor T-cell (CAR-T) therapy genetically engineers patient T cells to target myeloma antigens such as BCMA and GPRC5D, delivering deep and durable responses in relapsed/refractory myeloma.
Active Trials
15
Provinces
23
Centers
69
Active Studies (15)
Population synthesized by CMDNShowing 8 published English records of 15 registry trials.
Phase ITM20260016
RecruitingA Phase I Study of In Vivo CAR-T Therapy for Advanced Malignant Tumors (Multiple Myeloma, Lymphoma, Leukemia, Solid Tumors)
Target Population: Relapsed/refractory
Target: In situ (in vivo) CAR-T cell therapy targeting multiple targets including BCMA/GPRC5D/DLL3/FcRH5
Study Sites: Cancer Hospital, Chinese Academy of Medical Sciences
Phase IICTR20230238
RecruitingA Phase II, open-label, single-arm, multicenter clinical study evaluating the efficacy and safety of BCMA-targeted chimeric antigen receptor T-cell injection (CART-BCMA) in patients with relapsed/refractory multiple myeloma (RRMM)
Target Population: Relapsed/refractory
Target: BCMA-targeted chimeric antigen receptor T-cell (CAR-T) therapy
Study Sites: The First Affiliated Hospital, Zhejiang University School of Medicine、Union Hospital, Tongji Medical College, Huazhong University of Science and Technology、Beijing Jishuitan Hospital、The Affiliated Hospital of Hebei University 等 25 家中心
Phase ICTR20243438
RecruitingA Phase I Clinical Study of CBG002 CAR-T Cell Injection in Patients with Relapsed or Refractory Multiple Myeloma
Target Population: Relapsed/refractory
Target: BCMA-targeting CAR-T cell therapy
Study Sites: The First Affiliated Hospital, Zhejiang University School of Medicine、Union Hospital, Tongji Medical College, Huazhong University of Science and Technology、Sun Yat-sen University Cancer Center
Phase I
RecruitingA Clinical Study on the Safety, Tolerability, and Preliminary Efficacy of CR-2011 in Relapsed/Refractory Multiple Myeloma
Target Population: Relapsed/refractory
Target: In vivo chimeric antigen receptor T-cell (CAR-T) therapy targeting BCMA (based on mRNA-LNP technology)
Study Sites: Cancer Hospital Chinese Academy of Medical Sciences
Early Exploratory Clinical StudyNCT07622862
RecruitingAn Early Exploratory Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of BCMA/GPRC5D Dual-Targeted Allogeneic Universal CAR-T Cell Injection (DQ1001) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Target Population: Relapsed/refractory
Target: Allogeneic universal CAR-T targeting BCMA/GPRC5D
Study Sites: Zhongshan Hospital, Xiamen University
Phase INCT07620314
RecruitingAn Early Exploratory Clinical Study of the Safety and Efficacy of KSVCBD Injection in the Treatment of CD19- and/or BCMA-Positive B-Cell Malignancies
Target Population: Relapsed/refractory
Target: CD19, BCMA
Study Sites: Chinese PLA General Hospital (301 Hospital)
Phase Ib/IICTR20232814
RecruitingAn Open-Label, Multicenter Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of OriCAR-017 in Participants with Relapsed/Refractory Multiple Myeloma (MERCURY)
Target Population: Relapsed/refractory
Target: GPRC5D-targeted CAR-T
Study Sites: The First Affiliated Hospital, Zhejiang University School of Medicine、Shanghai Tongji Hospital、Jiangsu Province Hospital、Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 等 8 家中心
Early exploratory clinical studyNCT07715630
RecruitingIn Vivo-Generated PICX Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)
Target Population: Relapsed/refractory
Target: BCMA/CD70 CAR-T
Study Sites: The 920th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army